Does targeting ADAM-17 with an inhibitory monoclonal antibody have antitumour effects in triple-negative breast cancer cells?
Our in vitro findings suggest that targeting ADAM-17 with D1(A12) may have anticancer activity in TNBC cells.
RES has an immuno-suppressive property as well as protective effect on hepatocytes under allograft rejection. It might serve as a novel agent for reducing the severity of hepatic allograft rejection in rats.